Literature DB >> 26550542

Separation of β-amyloid binding and white matter uptake of (18)F-flutemetamol using spectral analysis.

Kerstin Heurling1, Christopher Buckley2, Rik Vandenberghe3, Koen Van Laere4, Mark Lubberink5.   

Abstract

The kinetic components of the β-amyloid ligand (18)F-flutemetamol binding in grey and white matter were investigated through spectral analysis, and a method developed for creation of parametric images separating grey and white matter uptake. Tracer uptake in grey and white matter and cerebellar cortex was analyzed through spectral analysis in six subjects, with (n=4) or without (n=2) apparent β-amyloid deposition, having undergone dynamic (18)F-flutemetamol scanning with arterial blood sampling. The spectra were divided into three components: slow, intermediate and fast basis function rates. The contribution of each of the components to total volume of distribution (VT) was assessed for different tissue types. The slow component dominated in white matter (average 90%), had a higher contribution to grey matter VT in subjects with β-amyloid deposition (average 44%) than without (average 6%) and was absent in cerebellar cortex, attributing the slow component of (18)F-flutemetamol uptake in grey matter to β-amyloid binding. Parametric images of voxel-based spectral analysis were created for VT, the slow component and images segmented based on the slow component contribution; confirming that grey matter and white matter uptake can be discriminated on voxel-level using a threshold for the contribution from the slow component to VT.

Entities:  

Keywords:  Alzheimer’s; kinetic modelling; molecular imaging; positron emission tomography; white matter disease

Year:  2015        PMID: 26550542      PMCID: PMC4620178     

Source DB:  PubMed          Journal:  Am J Nucl Med Mol Imaging


  23 in total

1.  Reduced retention of Pittsburgh compound B in white matter lesions.

Authors:  Lidia Glodzik; Henry Rusinek; Jinyu Li; Cyrus Zhou; Wai Tsui; Lisa Mosconi; Yi Li; Ricardo Osorio; Schantel Williams; Catherine Randall; Nicole Spector; Pauline McHugh; John Murray; Elizabeth Pirraglia; Shankar Vallabhajolusa; Mony de Leon
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-21       Impact factor: 9.236

2.  18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.

Authors:  Rik Vandenberghe; Koen Van Laere; Adrian Ivanoiu; Eric Salmon; Christine Bastin; Eric Triau; Steen Hasselbalch; Ian Law; Allan Andersen; Alex Korner; Lennart Minthon; Gaëtan Garraux; Natalie Nelissen; Guy Bormans; Chris Buckley; Rikard Owenius; Lennart Thurfjell; Gill Farrar; David J Brooks
Journal:  Ann Neurol       Date:  2010-09       Impact factor: 10.422

3.  Spectral analysis of dynamic PET studies.

Authors:  V J Cunningham; T Jones
Journal:  J Cereb Blood Flow Metab       Date:  1993-01       Impact factor: 6.200

4.  MR-based automatic delineation of volumes of interest in human brain PET images using probability maps.

Authors:  Claus Svarer; Karine Madsen; Steen G Hasselbalch; Lars H Pinborg; Steven Haugbøl; Vibe G Frøkjaer; Søren Holm; Olaf B Paulson; Gitte M Knudsen
Journal:  Neuroimage       Date:  2004-12-09       Impact factor: 6.556

5.  Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl-¹¹C]-2-(4'-methylaminophenyl)- 6-hydroxybenzothiazole.

Authors:  Bruno Stankoff; Leorah Freeman; Marie-Stéphane Aigrot; Audrey Chardain; Frédéric Dollé; Anna Williams; Damien Galanaud; Lucie Armand; Stéphane Lehericy; Catherine Lubetzki; Bernard Zalc; Michel Bottlaender
Journal:  Ann Neurol       Date:  2011-02-18       Impact factor: 10.422

6.  Strategies for the generation of parametric images of [11C]PIB with plasma input functions considering discriminations and reproducibility.

Authors:  Paul Edison; David J Brooks; Federico E Turkheimer; Hilary A Archer; Rainer Hinz
Journal:  Neuroimage       Date:  2009-07-08       Impact factor: 6.556

7.  Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.

Authors:  Natalie Nelissen; Koen Van Laere; Lennart Thurfjell; Rikard Owenius; Mathieu Vandenbulcke; Michel Koole; Guy Bormans; David J Brooks; Rik Vandenberghe
Journal:  J Nucl Med       Date:  2009-07-17       Impact factor: 10.057

8.  [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease.

Authors:  Shizuo Hatashita; Hidetomo Yamasaki; Yutaka Suzuki; Kumiko Tanaka; Daichi Wakebe; Hideki Hayakawa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-10-02       Impact factor: 9.236

9.  The use of spectral analysis to determine regional cerebral glucose utilization with positron emission tomography and [18F]fluorodeoxyglucose: theory, implementation, and optimization procedures.

Authors:  F Turkheimer; R M Moresco; G Lucignani; L Sokoloff; F Fazio; K Schmidt
Journal:  J Cereb Blood Flow Metab       Date:  1994-05       Impact factor: 6.200

10.  Quantification of [(11)C]PIB PET for imaging myelin in the human brain: a test-retest reproducibility study in high-resolution research tomography.

Authors:  Mattia Veronese; Benedetta Bodini; Daniel García-Lorenzo; Marco Battaglini; Salvatore Bongarzone; Claude Comtat; Michel Bottlaender; Bruno Stankoff; Federico E Turkheimer
Journal:  J Cereb Blood Flow Metab       Date:  2015-06-10       Impact factor: 6.200

View more
  5 in total

1.  Yes we can analyse amyloid images - Now What?

Authors:  Henryk Barthel; John Seibyl; Osama Sabri
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-05       Impact factor: 9.236

2.  Repurposing radiotracers for myelin imaging: a study comparing 18F-florbetaben, 18F-florbetapir, 18F-flutemetamol,11C-MeDAS, and 11C-PiB.

Authors:  Sylvain Auvity; Matteo Tonietto; Fabien Caillé; Benedetta Bodini; Michel Bottlaender; Nicolas Tournier; Bertrand Kuhnast; Bruno Stankoff
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-04       Impact factor: 9.236

3.  Evaluation of 18F-flutemetamol amyloid PET image analysis parameters on the effect of verubecestat on brain amlyoid load in Alzheimer's disease.

Authors:  Cyrille Sur; Katarzyna Adamczuk; David Scott; James Kost; Mehul Sampat; Christopher Buckley; Gill Farrar; Ben Newton; Joyce Suhy; Idriss Bennacef; Michael F Egan
Journal:  Mol Imaging Biol       Date:  2022-07-07       Impact factor: 3.488

4.  [18F]-Flutemetamol Uptake in Cortex and White Matter: Comparison with Cerebrospinal Fluid Biomarkers and [18F]-Fludeoxyglucose.

Authors:  Lisa Flem Kalheim; Tormod Fladby; Christopher Coello; Atle Bjørnerud; Per Selnes
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

5.  Spill-in counts in the quantification of 18F-florbetapir on Aβ-negative subjects: the effect of including white matter in the reference region.

Authors:  Francisco Javier López-González; Alexis Moscoso; Nikos Efthimiou; Anxo Fernández-Ferreiro; Manuel Piñeiro-Fiel; Stephen J Archibald; Pablo Aguiar; Jesús Silva-Rodríguez
Journal:  EJNMMI Phys       Date:  2019-12-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.